SGLT2 inhibitors reduced the risk of kidney disease progression by 30% (0·70, 0·50–1·00) in patients with ischaemic and hypertensive kidney disease, by 40% (0·60, 0·46–0·78) in patients with glomerular diseases, and by 26% (0·74, 0·51–1·08) in patients with other or unknown causes combined, although 95% CIs were wide. Here, SLC5A2 is linked to kidney disorder.